Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[3-methylsulfanylanilino]-6,7-dimethoxyquinazoline is a synthetic small molecule belonging to the quinazoline class. It has been studied primarily as a chemical probe and research compound rather than as an approved pharmaceutical drug. The compound exhibits potential biological activities including anticancer, anti-inflammatory, and antimicrobial effects in preclinical studies. Its mechanism of action is not fully characterized but may involve inhibition of protein kinases due to its structural similarity to other quinazoline derivatives known for kinase inhibition[1][4]. There are no approved medical indications or clinical trials reported for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[3-methylsulfanylanilino]-6,7-dimethoxyquinazoline.